The Takeda covalent BTK inhibitor clinical candidate, TAK-020 , is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune diseases based on a study in healthy volunteers. The molecule originated from a simple triazolone fragment, and overall is a [...]
< 1 minute read
Oct. 6, 2021
TAK-020: A Highly Selective Oral Covalent BTK Inhibitor
TAK-020
oral covalent BTK inhibitor >80% BTK occupancy <5 mg (Ph. I dose esc.) from fragment-based screen of 11k cmpds Journal of Medicinal Chemistry Takeda, San Diego, CA, USA
Loading...
